Jim Cramer told a 23-year-old Mad Money caller he could buy Voyager Therapeutics only because of the investor's long time horizon, warning the clinical-stage gene therapy company may take a lifetime to become profitable. The stock has dropped nearly 69% over ten years to $3.50, and the company reported a first-quarter net loss of $27.94 million on revenue of $2.59 million, missing consensus by over 70%. Analysts are bullish with 11 Buy ratings and an average target of $14.89, driven by the 2026 Alzheimer's trial dosing for VY1706, which reduced tau protein by up to 75% in preclinical studies. Risks include a recent CFO resignation, a charter amendment authorizing 240 million shares, and a beta above 1.25, making it a high-volatility bet even if the pipeline succeeds.
Voyager Therapeutics IncCramer warns long path to profitability; Q1 net loss and revenue miss; CFO resignation and share dilution risk
NVIDIA Corporation